Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Behavioral Medicine|November 14, 2015
A pilot study to improve adherence among MS patients who discontinue treatment against medical adviceJared Bruce, Amanda Bruce, Sharon Lynch, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|December 17, 2015
Being Kind to Your Future Self: Probability Discounting of Health Decision-MakingJared M Bruce, Amanda S Bruce, Delwyn Catley, et al.
Behavioural Processes|October 6, 2016
Using EP50 to forecast treatment adherence in individuals with multiple sclerosisDavid P Jarmolowicz, Derek D Reed, Amanda S Bruce, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2025
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trialJohn R Corboy, Robert J Fox, Gary Cutter, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2017
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trialChristopher LaGanke, Lawrence Samkoff, Keith Edwards, et al.
Journal of Molecular Biology|August 24, 2019
Processive Recoding and Metazoan Evolution of Selenoprotein P: Up to 132 UGAs in MolluscsJaninah Baclaocos, Didac Santesmasses, Marco Mariotti, et al.
Contemporary Clinical Trials|July 3, 2021
Modifying Diet and Exercise in MS (MoDEMS): Study design and protocol for a telehealth weight loss intervention for adults with obesity & Multiple SclerosisJared M Bruce, Julia S Cozart, Robin P Shook, et al.
International Journal for Parasitology. Parasites and Wildlife|December 17, 2024
Morphological vs. molecular identification of trematode species infecting the edible cockle Cerastoderma edule across EuropeLeslie Stout, Guillemine Daffe, Aurélie Chambouvet, et al.
Heredity|August 18, 2023
Heterogeneous microgeographic genetic structure of the common cockle (Cerastoderma edule) in the Northeast Atlantic Ocean: biogeographic barriers and environmental factorsManuel Vera, Sophie B Wilmes, Francesco Maroso, et al.
Clinical Therapeutics|July 22, 2008
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot studyBarrie J Hurwitz, Douglas Jeffery, Barry Arnason, et al.
Pageof 5